Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: Three-year results of the DEBATE-ISR study

Journal of Endovascular Therapy

Volumn 23, Issue 1, 2016, Pages 52-57

  Grotti, Simone ^a   Liistro, Francesco ^a   Angioli, Paolo ^a   Ducci, Kenneth ^a   Falsini, Giovanni ^a   Porto, Italo ^a,b   Ricci, Lucia ^a   Ventoruzzo, Giorgio ^a   Turini, Filippo ^a   Bellandi, Guido ^a   Bolognese, Leonardo ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Diabetes; Drug coated balloon; Femoropopliteal segment; In stent restenosis; Paclitaxel eluting balloon; Peripheral artery disease; Popliteal artery; Restenosis; Stent; Superficial femoral artery; Target lesion revascularization

Indexed keywords

PACLITAXEL; CARDIOVASCULAR AGENT;

AGED; ARTERY OCCLUSION; ARTICLE; BALLOON; CLAUDICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DIABETIC PATIENT; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; KAPLAN MEIER METHOD; MALE; PACLITAXEL ELUTING BALLOON; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; POPLITEAL ARTERY; PRIORITY JOURNAL; REVASCULARIZATION; SUPERFICIAL FEMORAL ARTERY; TARGET LESION REVASCULARIZATION; TOSAKA CLASS III OCCLUSION; ADVERSE EFFECTS; CHI SQUARE DISTRIBUTION; CRITICAL ILLNESS; DEVICES; DIABETIC ANGIOPATHIES; DIAGNOSTIC IMAGING; DRUG ELUTING STENT; EPIDEMIOLOGY; FEMORAL ARTERY; ISCHEMIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDY; PROSTHESIS DESIGN; RECURRENT DISEASE; REGISTER; RETREATMENT; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; STENOSIS, OCCLUSION AND OBSTRUCTION; TIME FACTOR; TREATMENT OUTCOME; VASCULAR PATENCY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CONSTRICTION, PATHOLOGIC; CRITICAL ILLNESS; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; FEMORAL ARTERY; HISTORICALLY CONTROLLED STUDY; HUMANS; ISCHEMIA; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RECURRENCE; REGISTRIES; RETREATMENT; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 84957812546     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1177/1526602815614555     Document Type: Article

References (37)

1. TASC Steering Committee, Jaff MR, White CJ, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-The-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Endovasc Ther. 2015;22:663-677.
2. European Stroke Organisation, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2851-2906.
3. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888.
4. Laird JR, Katzen BT, Scheinert D, et al; RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.
5. Byrne RA, Joner M, Alfonso F, et al. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014;11:13-23.
6. Laird JR, Yeo KK, Rocha-Singh K, et al. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery instent restenosis: twelve-month results from the SALVAGE study. Catheter Cardiovasc Interv. 2012;80:852-859.
7. Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013;6:274-281.
8. Stabile E, Virga V, Salemme L, et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012;60:1739-1742.
9. Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol. 2006;48:1573-1578.
10. Yeo KK, Malik U, Laird JR. Outcomes following treatment of femoropopliteal in-stent restenosis: a single center experience. Catheter Cardiovasc Interv. 2011;78:604-608.
11. Schmidt A, Zeller T, Sievert H, et al. Photoablation using the turbo-booster and excimer laser for in-stent restenosis treatment: twelve-month results from the PATENT study. J Endovasc Ther. 2014;21:52-60.
12. Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology. 2008;248:297-302.
13. Liistro F, Angioli P, Porto I, et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J Endovasc Ther. 2014;21:1-8.
14. Virga V, Stabile E, Biamino G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery instent restenosis: 2-year follow-up. JACC Cardiovasc Interv. 2014;7:411-415.
15. Banning AP, Lim CC. Drug-eluting balloons: what is their place on the interventionalist's shelf? Heart. 2010;96: 1257-1258.
16. Liistro F, Angioli P, Grotti S, et al. Impact of critical limb ischemia on long-term cardiac mortality in diabetic patients undergoing percutaneous coronary revascularization. Diabetes Care. 2013;36:1495-500.
17. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16-23.
18. Laird JR, Yeo KK. The treatment of femoropopliteal instent restenosis: back to the future. J Am Coll Cardiol. 2012;59:24-25.
19. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495-502.
20. Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6:1295-1302.
21. Cortese B, Granada JF, Scheller B, et al. Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document [published online May 24, 2015]. Eur Heart J. doi:10.1093/eurheartj/ehv204.
22. Iijima R, Araki T, Nagashima Y, et al. Incidence and predictors of the late catch-up phenomenon after drug-eluting stent implantation. Int J Cardiol. 2013;168:2588-2592.
23. Sgueglia GA, Cortese B, Gaspardone A. Late catch-up phenomenon after drug-eluting balloon angioplasty. Int J Cardiol. 2013;168:638-639.
24. Hehrlein C, Dietz U, Kubica J, et al. Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis first-in-man (PEPPER) trial. Cardiovasc Revasc Med. 2012;13:260-264.
25. Posa A, Nyolczas N, Hemetsberger R, et al. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries. Catheter Cardiovasc Interv. 2010;76:395-403.
26. Scheller B, Clever YP, Kelsch B, et al. Long-term followup after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv. 2012;5:323-330.
27. Tepe G, Schnorr B, Albrecht T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102-108.
28. Herten M, Torsello GB, Schonefeld E, et al. Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis. J Vasc Surg. 2015;61:394-399.
29. Johnson DE, Hinohara T, Selmon MR, et al. Primary peripheral arterial stenoses and restenoses excised by transluminal atherectomy: a histopathologic study. J Am Coll Cardiol. 1990;15:419-425.
30. Edlin RS, Tsai S, Yamanouchi D, et al. Characterization of primary and restenotic atherosclerotic plaque from the superficial femoral artery: potential role of Smad3 in regulation of SMC proliferation. J Vasc Surg. 2009;49: 1289-1295.
31. Patterson C, Mapera S, Li HH, et al. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol. 2006;26:1473-1480.
32. Zhou XC, Huang RC, Zhang B, et al. Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents on interleukin-1β-induced coronary artery in-stent restenosis in pigs. Chin Med J (Engl). 2010;123:2405-2409.
33. Stampfl U, Radeleff B, Sommer C, et al. Paclitaxel-induced arterial wall toxicity and inflammation: part 2-long-term tissue response in a minipig model. J Vasc Interv Radiol. 2009;20:1608-1616.
34. Carter A, Murphy MO, Turner NJ, et al. Intimal neovascularisation is a prominent feature of atherosclerotic plaques in diabetic patients with critical limb ischaemia. Eur J Vasc Endovasc Surg. 2007;33:319-324.
35. Speck U, Cremers B, Kelsch B, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Intervent. 2012;5:392-400.
36. Milewski K, Afari ME, Tellez A, et al. Evaluation of efficacy and dose response of different paclitaxel-coated balloon formulations in a novel swine model of iliofemoral in-stent restenosis. JACC Cardiovasc Interv. 2012;5: 1081-1088.
37. Zhao HQ, Nikanorov A, Virmani R, et al. Late stent expansion and neointimal proliferation of oversized nitinol stents in peripheral arteries. Cardiovasc Interv Radiol. 2009;32:720-726.